Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis

Italian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 5, 1997, Pages 441-447

  Colombatto, P ^a   Oliveri, F ^a   Leandro, G ^a   Baldi, M ^a   Capalbo, M ^a   Rocca, G ^a   Brunetto, M R ^a   Bonino, F ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Alpha interferon; Chronic viral hepatitis; Platelets; White blood cells

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG CHOICE; FEMALE; HEMATOPOIETIC SYSTEM; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; THROMBOCYTE COUNT; TOXICITY; VIRUS HEPATITIS;

ADULT; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; LEUKOCYTE COUNT; MALE; PLATELET COUNT;

EID: 0031406860     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Isacs A, Lindemann J. Virus interference. 1. The interferons. Proceedings of the Royal Society of London (Biology) 1957;147:258-67.
2. Stewart WEI. The Interferon System. New York: Springer-Verlag, 1979.
3. Borden EC, Fall LA. Interferons: biological, cell growth, inhibitory, and immunological effects. Progr Hematol 1981;12:299-339.
4. Finter NB. The classification and biological functions of the interferons. A review. J Hepatol 1986;3(Suppl 2): 157-60.
5. Takano S, Satomura Y, Omata M, and the Japan Acute Hepatitis Cooperative Study Group. Effects of interferon beta on non A non B acute hepatitis: a prospective, randomized, controlleddose study. Gastroenterology 1994;107:805-11.
6. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Sem Liver Dis 1995;15:82-91.
7. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Advan Intern Med 1994;39:241-75.
8. Fattovich G, Giustina G, Favarato S, Ruol A, and Investigators of the Italian Association for the Study of the Liver. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996;24:38-47.
9. Bottomley JM, Toy JL. Clinical side effects and toxicities of interferons. In: Interferon. Vol. 4, Finter NB, Oldham RK editors, Amsterdam: Elsevier, 1985;155-80.
10. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992;102:2155-60.
11. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon alfa therapy for chronic hepatitis C. Am J Gastroenterol 1994:89:399-403.
12. Baudine E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemonnier C. Reversibility of thyroid dysfunction induced by recombinant a interferon in chronic hepatitis C. Clin Endocrinol 1993:39:657-61.
13. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993:18:253-7.
14. Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, Longo DL. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte interferon therapy for mycosis fungoides. N Eng J Med 1984:310:32-5.
15. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991:115:178-83.
16. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989:10:24-8.
17. Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, et al. Autoantibodies during alpha-interferon therapy for chronic hepatitis B. J Med Virol 1991:34:132-5.
18. Pawlotsky JM, Yahia MB, André C, Voisin MC, Intrator L, Roudot-Thoraval F, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8.
19. Pawlotsky JM, Dhumeaux D, Bagot M. Hepatitis C virus in dermatology. A review. Arch Dermatol 1995; 131:1185-93.
20. Fabris P, Betterle C, Floreani A, Greggio NA, De Lazzari F, Naccarato R, et al. Development of type I diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340;548.
21. Garancini P, Gallus G, Calori G, Formigaro F, Micossi P. Incidence and prevalence rates of diabetes mellitus in Italy from routine data: a methodological assessment. Eur J Epidemiol 1991;7:55-63.
22. Obaid Shakil A, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. J Hepatol 1996:24:38-47.
23. Smedley H, Katrak M, Sikora K, Wheeler T. Neurological effects of recombinant human interferon. Br Med J Clin Res 1983:286:262-4.
24. Renault PF, Hoofnagle JH, Park Y, Müllen HD, Peters M, Jones DB, et al. Psychiatrie complications of long term interferon alfa therapy. Arch Intern Med 1987:147:1577-80.
25. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatrie morbidity: An investigation in a trial of recombinant alpha-interferon in hepatitis B carriers. Lancet 1987;2:1175-8.
26. Janssen HLA, Berk L, Vermeulen M, Shalm SW. Seizures associated with low dose alpha-interferon. Lancet 1990;2:1580.
27. Janssen HLA, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-3.
28. McLaughlin P, Talpaz M, Quesada JR. Immune thrombocytopenia following alpha interferon therapy in patients with cancer. JAMA 1985;254:1353-4.
29. Kassianides C, Di Bisceglie AM, Hoofnagle JH. Alpha interferon therapy in patients with decompensated chronic type B hepatitis. In: Zuckerman AJ editor. Viral hepatitis and liver disease. New York: Alan R Lyss, 1988:864-8.